Physician profile
Nisha Ali
NPI 1154773943
$5,031.21
in general payments reported to CMS, 2019-2025
22 companies · $25.52 in 2025
The $25.52 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,496 · 2022: $1,146 · 2023: $798 · 2024: $566 · 2025: $25.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Education: $46.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.36 |
| Education | $46.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,603.87 | 2021-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $423.58 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $285.59 | 2021-2023 | Lifevest |
| Boston Scientific Corporation | $257.80 | 2021-2023 | |
| Shockwave Medical, INC | $181.62 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $160.96 | 2022-2024 | (6342) Intrasight Integrated |
| Merck Sharp & Dohme LLC | $145.08 | 2022-2024 | Verquvo |
| Astellas Pharma US INC | $140.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $121.40 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $112.63 | 2021-2022 | |
| Abiomed | $102.48 | 2022-2024 | Impella |
| Biotronik INC. | $83.09 | 2022 | |
| Lantheus Medical Imaging, INC. | $78.80 | 2021-2022 | |
| Daiichi Sankyo INC. | $55.95 | 2023 | Injectafer |
| Amgen INC. | $52.05 | 2021-2023 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $47.60 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $41.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $36.62 | 2022 | |
| Ge Healthcare | $35.20 | 2024 | |
| Bridgebio Pharma, INC. | $25.52 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $19.95 | 2023 | |
| Biosense Webster, INC. | $19.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.